

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北控醫療健康產業集團有限公司

Beijing Enterprises Medical And Health Industry Group Limited

(formerly known as Genvon Group Limited 正峰集團有限公司)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2389)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO THE ANNUAL REPORT OF THE COMPANY FOR
THE YEAR ENDED 31 DECEMBER 2014**

The board (the “**Board**”) of directors (the “**Directors**”) of Beijing Enterprises Medical and Health Industry Group Limited (the “**Company**”) makes this announcement in relation to its annual report for the year ended 31 December 2014 published on 13 April 2015 (the “**Annual Report**”). Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as defined in the Annual Report.

The Company would like to provide the following additional information which should be included in the Annual Report relating to:

- (1) the Subscription; and
- (2) the 2013 Scheme.

In addition to the information under note 30(d) to the consolidated financial statements of the Company as set out on page 95 of the Annual Report, the Board would like to supplement that (1) the aggregate nominal value of the ordinary shares of the Company issued under the Subscription as at 31 July 2014, being the date of completion of the Subscription, was HK\$40,000,000 of the then par value of HK\$0.1 per share (before the consolidation of 2 shares into 1 share of the Company being effective on 5 March 2015 (the “**Share Consolidation**”)); and (2) after deducting the related expenses of approximately HK\$1,950,000, the net price per Subscription Share issued was approximately HK\$0.32 per share (before the Share Consolidation).

The Board also wishes to disclose further information under note 31 to the consolidated financial statements of the Company as set out on page 97 of the Annual Report that (1) the total number of securities available for issue under the 2013 Scheme was 423,133,750 shares, representing 10.0% of the issued share capital of the Company on 24 May 2013, being the date of adoption of the 2013 Scheme, and approximately 4.2% of the issued share capital of the Company on 27 March 2015 (after taking into account the Share Consolidation), being the date of the Annual Report; and (2) the remaining life of the 2013 Scheme, which will expire on 23 May 2023, is approximately 8.2 years from the date of the Annual Report.

The above additional information does not affect other information contained in the Annual Report and the contents of the Annual Report remain correct and unchanged.

By Order of the Board
**Beijing Enterprises Medical and Health
Industry Group Limited**
Zhu Shi Xing
Chairman

Hong Kong, 29 July 2015

As at the date of this announcement, the Board comprises seven executive Directors, namely Mr. Zhu Shi Xing, Mr. Liu Xue Heng, Mr. Gu Shan Chao, Mr. Hu Xiao Yong, Mr. Hu Shiang Chi, Mr. Wang Zheng Chun and Mr. Zhang Jing Ming; one non-executive Director, namely Mr. Robert Winslow Koepf and four independent non-executive Directors, namely Mr. Xie Ming, Mr. Tse Man Kit, Keith, Mr. Wu Yong Xin and Mr. Zhang Yun Zhou.